Medicinal Cannabis and Complex Mental Health: Lessons from the Oliver Robinson Inquest
A recent coroner’s ruling has sparked a critical conversation about the safety and regulation of medicinal cannabis prescriptions for patients with severe mental health conditions. The inquest into the death of 34-year-old Oliver Robinson from Bury concluded that his private prescription for medicinal cannabis contributed to his death, acting as a barrier to the psychiatric and addiction care he desperately needed.
The Case of Oliver Robinson
Oliver Robinson was a talented artist and former property consultant who struggled for years with depression, anxiety and bipolar disorder. His history included two inpatient admissions to The Priory, a mental health and addiction rehab clinic, in 2019 and late 2020. While he initially responded well to treatment, a depressive episode in early 2022 led him to seek an alternative path.
In April 2022, Robinson enrolled in a research study run by the London-based Curaleaf Clinic. Between May 7, 2022, and November 17, 2023, he received private prescriptions for medicinal cannabis intended to treat “treatment-resistant depression.” It’s important to note that while medicinal cannabis was legalized in the UK in 2018, it is prescribed for depression “off-licence,” meaning it is not officially licensed for that specific condition.
A Downward Spiral of Dependence
What began as a medical attempt to manage depression evolved into a severe dependency. His brother, Alexander, described a harrowing transformation, noting that Oliver became angry, violent, and aggressive. He reportedly punched holes in walls and threatened to firebomb his home and car when he was unable to access his supply.
The inquest revealed a dangerous cycle: when Robinson could not afford his private prescriptions, he sourced “illicit” street cannabis as a substitute. This led to a dual diagnosis from an NHS psychiatrist in April 2023 of “recurrent depressive disorder and mental and behavioural disorder due to cannabinoid dependency.”
Coroner’s Findings: An “Obstacle” to Care
HM Area Coroner Catherine McKenna recorded a verdict of death by misadventure after Robinson took his own life on November 24, 2023. In a “prevention of future deaths report,” the coroner highlighted a systemic failure in the intersection of private and public healthcare.
Despite the NHS diagnosis of cannabinoid dependency, the Curaleaf Clinic continued to issue prescriptions. Coroner McKenna ruled that these continuing prescriptions “acted as an obstacle” to Robinson receiving the appropriate psychiatric and addictions care. Essentially, the medical legitimacy of the prescription provided a shield that hindered the intervention of addiction services.
The Broader Medical Debate
The tragedy has highlighted a divide between private clinic practices and psychiatric expertise. While the private clinic maintains that its decisions are informed by an evidence base and made by multi-disciplinary teams, other experts argue there’s a significant lack of evidence that cannabis helps with serious mental health issues. In some cases, these substances may actually exacerbate the condition.
- Off-Licence Risks: Prescribing cannabis for conditions it isn’t licensed for (like depression) can lead to unpredictable outcomes.
- Dependency Traps: Patients may turn to illicit street sources if they cannot afford private medical prescriptions.
- Care Interference: Medical prescriptions can inadvertently obstruct patients from accessing necessary addiction and psychiatric services.
- Vulnerable Populations: Patients with complex mental health histories, such as bipolar disorder, may be at higher risk of adverse reactions to cannabinoid dependency.
Looking Forward: The Call for Tighter Regulation
In response to his brother’s death, Alexander Robinson has launched a campaign to tighten the rules regarding access to medicinal cannabis, specifically for patients with complex mental health needs. The goal is to ensure that private prescriptions do not supersede the need for comprehensive, integrated psychiatric care.
As the medical community continues to evaluate the role of cannabinoids in mental health, the Oliver Robinson case serves as a stark reminder that medical prescriptions are not without risk—especially when they occur in isolation from a patient’s broader clinical history and addiction profile.
Frequently Asked Questions
Why was the verdict “death by misadventure”?
The coroner used this verdict to describe the tragic circumstances where the continuation of medicinal cannabis prescriptions contributed to a lack of appropriate care, ultimately leading to the patient taking his own life.
Is medicinal cannabis legal for depression in the UK?
While medicinal cannabis is legal in the UK, it is not licensed for the treatment of depression. When it is prescribed for this purpose, it is considered an “off-licence” prescription.
What is “cannabinoid dependency”?
As seen in this case, it refers to a physical and psychosocial dependence on cannabis, which can manifest as aggression, irritability, and a desperate need to source the drug through any means necessary when the supply is interrupted.